targeting of erbB3 with MM-121/SAR256212 enhances paclitaxel
|
Re: targeting of erbB3 with MM-121/SAR256212 enhances paclitaxel
Thanks Hopeful,
I'm always on the lookout for unicorns. I found Merrimack Pharma's pipeline and see they also have MM302 in the pipeline for advanced Her2 breast cancer: MM-302 (Nanotherapeutic)
Doxorubicin is also known as Doxil, or Adriamycin. |
Re: targeting of erbB3 with MM-121/SAR256212 enhances paclitaxel
Here is the Merrimack Pharma's pipeline info for MM-121:
MM-121 (Signaling Inhibitor)
|
Re: targeting of erbB3 with MM-121/SAR256212 enhances paclitaxel
MM-121
MM-121/SAR256212 is a fully human monocolonal antibody that targets the HER3 receptor. Merrimack’s Network Biology approach identified HER3 as a critical tumorigenic node in several types of cancer. Heregulin-induced signaling of HER3 activates cellular pathways promoting the development, growth and progression of cancer. In addition, it is generally believed that HER3 activation serves as a compensatory mechanism by which cancer cells develop resistance to targeted therapies, many chemotherapies, and anti-hormonal therapies. MM-121 functions by inhibiting ligand-induced signaling through HER3 and activation of associated survival pathways. Our research suggests that combining MM-121 with other therapies could provide clinical benefit by:
MM-121 in the Clinic MM-121 is currently being tested in a broad clinical development program in collaboration with Sanofi Oncology. This partnership investigates MM-121 in combination with several therapies across multiple patient populations. At this time there are several Phase 2 clinical trials spanning various patient populations including:
CLICK HERE to learn more about MM-121 in the clincic |
All times are GMT -7. The time now is 04:04 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021